论文部分内容阅读
目的 研究匹维溴铵、双歧三联活菌和氟西汀合用治疗难治性肠易激综合征 (IBS) (便秘型 )的临床疗效。方法 对 62例难治性IBS(便秘型 )患者予以匹维溴铵 5 0mg ,每日 3次 ,双歧三联活菌 2 0 ,每日 2次 ,氟西汀10mg ,每日 1次 ,共 8周 ,治疗完成后连续随访 12周。结果 62例中 5 8例完成了随访 ( 93 5 4% )。腹痛、腹胀缓解率为 79 3 1% ,便秘完全缓解 17例 ( 2 9 3 1% ) ,部分缓解 3 2例 ( 5 5 91% ) ,不缓解 9例 ( 15 5 1% )。心理障碍完全缓解 2 2例 ( 3 7 93 % ) ,部分缓解 3 0例 ( 5 1 72 % ) ,不缓解 6例 ( 10 3 4% )。结论 匹维溴铵、双歧三联活菌和氟西汀合用治疗难治性IBS(便秘型 )有一定疗效
Objective To study the clinical efficacy of pividium bromide, bifidobacterium live together and fluoxetine in the treatment of refractory irritable bowel syndrome (IBS) (constipation type). Methods 62 patients with refractory IBS (constipation type) were treated with pinaverium bromide 50 mg three times a day, bifid triple viable bacteria 20, twice a day, fluoxetine 10 mg once daily 8 weeks, followed up for 12 weeks after the completion of treatment. Results Fifty-two of the 62 patients completed follow-up (93 54%). Abdominal pain, abdominal distension rate was 79 3 1%, complete constipation was relieved in 17 cases (2 9 3 1%), partial remission 32 cases (5 91%), 9 cases (15 5 1%) were not relieved. There were 22 cases (3793%) of complete psychological relief, 30 partial remission (51.72%) and 6 (103%) non-remission. Conclusions Pivivirin, bifidobacterium triadimeticum and fluoxetine have a certain curative effect in the treatment of refractory IBS (constipation type)